PNC Financial Services Group’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
PNC Financial Services Group's TVRD Position: Q1 2026 in Review
PNC Financial Services Group increased its Tvardi Therapeutics (TVRD) stake by 77% in Q1 2026, buying an estimated $882 and bringing the position to 519 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #4639.
PNC Financial Services Group first reported a position in TVRD in Q4 2016 and has held it in 30 quarters since. The position peaked at $70K in Q2 2017. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- PNC Financial Services Group held 519 shares of Tvardi Therapeutics worth $1.65K as of Q1 2026.
- PNC Financial Services Group bought 225 Tvardi Therapeutics shares in Q1 2026, an estimated $882.
- Tvardi Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4639 holding.
- PNC Financial Services Group first reported a position in Tvardi Therapeutics in Q4 2016 and has held it in 30 quarters since.
- PNC Financial Services Group's Tvardi Therapeutics position peaked at $70K in Q2 2017.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.